Nimbus Therapeutics
Curated by SignalDeveloper of targeted therapeutics for cancer, metabolic and inflammatory diseases
Overview
Developer of targeted therapeutics for cancer, metabolic and inflammatory diseases. The lead candidate targets ACC for Nonalcoholic Steatohepatitis (NASH). The other drug candidate is an IRAK4 inhibitor used to target Tyk2 and KRas that mediates immune signaling.
Key facts
- Founded
- 2009
- Headquarters
- Cambridge, United States
- Stage
- Sign up to view
- Industry
- Life Sciences Technology
Business model
- 4 products and services
- Sign up to view
Contact
- Primary office
- Sign up to view
- Sign up to view
- Phone
- Sign up to view
Open roles
2 rolesDirector/Senior Director, Nonclinical Safety (Toxicology)
Boston, MA · On-site · Volunteer
Executive Director, Nonclinical Safety (Pathology & Toxicology)
Boston, MA